Drugs / Recombinant Herpes Zoster Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07633197 | May → Dec 2026 expected | viral infectious disease | Changchun BCHT Biotechnology Co. | Enrolling by invitation | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06088745 | Sep 2023 → Dec 2024 overdue | herpes zoster | Beijing Luzhu Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05879419 Comparator | May 2023 → Dec 2025 overdue | Behcet disease, Sjogren syndrome, ankylosing spondylitis, juvenile dermatomyositis +4 | University of Sao Paulo General Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Herpes Zoster Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05879419 ↗ |
| Known as | RZV | “Recombinant Herpes Zoster Vaccine (RZV)” NCT05879419 ↗ |
| Modality | Vaccine | “a recombinant vaccine against HZ (RZV or Shingrix®)” NCT05879419 ↗ |
| Route | Intramuscular | “Vaccine will be administered (0.5 ml) into the deltoid muscle at inclusion and 6 weeks (two doses).” NCT05879419 ↗ |